Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma

NCT00086216 is registered in ClinicalTrials.gov with Callisto Pharmaceuticals as lead sponsor.

NCT NCT00086216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma
Lead sponsor
Callisto Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2004
Completion date
November 30, 2007
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma